newsfilter
← Latest News
GlobeNewswire·

Affimed Reports Third Quarter 2024 Financial Results & Business Update

AFM24 combination with atezolizumab: The non-small cell lung cancer (NSCLC) EGFR wild-type (EGFRwt) cohort completed enrollment: Objective response rate (ORR) and safety data to be presented on a Company conference call